|Title:||United States top 20 pharmaceutical companies ranked by direct-to-consumer advertising in dollars and percent change for 2011|
|Source:||Medical Marketing & Media|
Start of full article - but without data
Top XX companies by DTC spending, 2011
Rank Company US DTC % change media $ (XXXs) * prior year
X Pfizer $XXX,XXX.X -X% X Eli Lilly $XXX,XXX.X X% X AstraZeneca $XXX,XXX.X -X% X GlaxoSmithKline $XXX,XXX.X -XX% X Boehringer Ingelheim $XXX,XXX.X XXX% X Merck $XXX,XXX.X -XX% X Abbott Labs $XXX,XXX.X XX% X Allergan $XXX,XXX.X -X% X Amgen $XXX,XXX.X XXX% XX Otsuka $XXX,XXX.X -XX% XX Takeda $XXX,XXX.X XX% XX Novartis $XXX,XXX.X XX% XX Bristol-Myers Squibb $XX,XXX.X -XX% XX Sumitomo $XX,XXX.X -XX% XX Novo Nordisk $XX,XXX.X XXX% XX Bayer $XX,XXX.X -XX% XX Roche $XX,XXX.X -XX% XX Johnson & Johnson $XX,XXX.X -XX% XX BMS/Sanofi $XX,XXX.X -XX% XX Sanofi $XX,XXX.X -XX%
* Total spent comprises brodacast, print, outdoor and BXB, but not
The prescription drug ads of tomorrow won't interrupt our favorite TV show to suggest that we ask our doctor about some pill to treat a condition we probably don't have, and they won't take us on scenic walks through summer meadows or along pristine beaches. More likely than not. they'll be promoting specialty drugs and biologics indicated for treatment of exactly the diseases we do have. They'll be hyper-targeted and hyper-specific.
The media world is transforming at a blistering pace, with much of the action shifting from TV to Web to mobile and social just in the past few years, and ad spend (along with prices) catching up but still well behind the times. At the same time, the profile of branded drugs is changing with equal rapidity as the mass-market blockbusters that served as the engine of industry revenues for the past decade go off-patent and are replaced by an array of smaller products, including biologics, vaccines, devices and diagnostics.
Of the XX biggest advertisers among prescription drug brands of 2011. three have already gone off patent, including top-spending Lipitor ($XXX million for the year), AstraZeneca's Seroquel XR ($XX million) and Pfiper's Viagra ($XXX million). Bristol - I Myers Squibb/Sanofi's Plavix. which spent $XX million for the XX months to September, loses patent exclusivity next month. Five years from now, brands that spent $ X.X billion on measured CFTC media in XXX I. according to Nielsen data, will have lost patent protection. Almost all of those products will face generic competition, the exceptions being biologics like Pfizer/Amgen's Enbrel and drug-device combos like Glaxo-SmithKline's Advair Diskus.
There will be new products, of course, to replace those going generic. Consumers will still need to be educated on their conditions and treatment options. Manufacturers will still do much of that through good old-fashioned advertising. But the drugs and biologics coming down the pipeline are very different from the old mass-market, primary care-focused, strictly small-molecule blockbusters of old. and marketing them--to smaller audiences, using smaller budgets--will require a whole new set of tools.
Fortunately, they're set to hit the market just as emerging digital technologies make more precise targeting possible and, compared to buying airtime. more affordable.
Enbrel straddles the old and the new in DTC. On the one hand. the Pfizer/Ameen joint venture is a mature mega-bloekbuster that's made its makers tens of billions of dollars over the XX years it's been on the market. On the other, it's a complex biologic injectable, and people with the various immunological disorders it treats are far less numerous than, say, sufferers of seasonal allergies, insomnia or depression.
"What you find here is a much more targeted approach in terms of knowing vour customer and how best to communicate to them, via what channels." says Pfizer's John Miles, VP of sales and marketing for Enbrel in the US. "We use a very integrated approach with Enbrel. It's not completely novel--we're usingTV and print as you would normally see it--but where we go into the digital space, there are opportunities where we know who our customers are, and we're very specific in types of initiatives, whether it's search or display advertising. We know where our patients and physicians are."
For Enbrel, Pfizer and Amgen are currently running a campaign rooted in a venerable old lactic--the celebrity sufferer, in this case pro golfer Phil Mickelson, who revealed in 2010 that he had been diagnosed with psoriatic arthritis and prescribed the biologic. The companies launched a campaign featuring Miekelson last November, with Abelson-Taylor handling creative.
"Phil is such an inspiring spokesperson for patients with psoriatic arthritis, and it's a condition that has not received a tremendous amount of press" says Dominique Monnet, VP general manager of the inflammation business unit at Amgen.
Psoriatic arthritis afflicts around one in twenty of the in twentyo f the X% of Americans who suffer from psoriasis. As with other rheumatic conditions, the disase is under-diagnosed and treated, and as with rheumatoid arthritis, early intervention is critical to prevent permanent joint damate.
Enbrel is indicated for five conditions, including psoriatic arthritis, plaque psoriasis, rheumatoid arthritis, juvenile idiopathic arthritis and ankylosing spondylitis. Altogether, rheumatoid diseases affect around X% of the US population. The joint venture has also recently launched a separate campaing aimed a separate campaing aimed at sufferers of plaque psoriasis. The brand.com bridges all the indications.
"You're daling with different patients with thers indications, so it's important that we really look at the different channels available to us and communicate appropriately to them," says Miles. "So we have a clear direction with rheumatology and a really clear but independent direction with our dermatology approach."
Niche brands, big plays
J&J's Janssen Biotech is using aspirational messaging--along with a bit of star power--to promote its Stelara for plaque psoriasis.
"Psoriasis patients suffer from a range of physical, emotional and treatment burdens related to their condition," says Janssen Biotech's David Fabbri, director of dermatology marketing, "so our main goal is to instill hope for clearer skin. With that in mind, all our messaging focuses on the idea that they can 'imagine the possibilities of clearer skin.'"
In addition to branded ads and a website touting its "Stories" testimonials, including that of America's Next Top Model winner CariDee English, the Stelara team is also running an unbranded education campaign, developed in partnership with the National Psoriasis Foundation, called "Are You Serious?"The effort, which launched at the end of 2010 with a humorous viral video starring comedian and sufferer Jon Lovitz, includes a patient-focused online platform soliciting stories of coping with the disease from patients. Draftfcb Chicago handled creative while Universal McCann's JX, Ansible and Razorfish worked on other aspects of the campaign.
Stelara also hosts "Fit in Your Skin," an online health and wellness program for psoriasis sufferers led by fitness expert Jackie Warner (Amgen and Pfizer ran unbranded awareness ads early on, "when biologic therapy was new and we really needed to educate patients," says Pfizer's Miles, but have since shifted to a strictly branded approach). From QX XX to QX 'XX, Stelara spent $XX million.
Like Stelara, Takeda's Uloric launched recently. As the first new-product for gout on the market in four decades, the Uloric team had some work to do in educating patients about how the disease works and available treatments.
"Our campaign was really focused on targeting patients who were on treatment but were still experiencing flares," says Heidi Gillmore, marketing director for Uloric. ''There was a big awareness gap because of the fact that there's been no new innovation in the category for decades, and therefore no promotion happening.There was really a lack of credible resources on the Internet."
While the disease is most often treated by primary care physicians, the market for gout drugs is a niche one, with around eight million adults diagnosed in the US, and just short of three million treated chronically. Because there's a lot of co-morbidity, the topic often fails to come up during doctor visits, as more immediate health concerns predominate. Around half of those on treatment are still experiencing flares, according toTakeda's research, which also found poor patient understanding of the role of hyperuricemia, the underlying metabolic condition treated by Uloric, in gout.
"So that fed into our strategy behind doing a really broad-based, multichannel, branded and unbranded campaign to both educate on the disease state and introduce the brand as an option to these patients," says Gillmore. Takeda took a two-pronged approach, the unbranded fork being ads that featured a real doctor talking about the role that uric acid plays in gout along with the tagline ifcGout can attack silently even between flares." Branded ads feature patients lugging around a large flask of liquid that serves as a metaphor for uric acid reduction. Both efforts drive viewers to goutinfo.com/rhe brand is now moving to put more emphasis on relationship marketing.
"Now that we've built this awareness level, we're really trying to drive more dialogue between patients and physicians," says Gillmore. "So we're starting to step away from the awareness-building vehicles like theTV ads and center more on the action vehicles--online and in-office media."
Gout is one of the most-searched conditions, says Gillmore, and Takeda research has shown that four out of live patients searching for gout info online are currently suffering a gout attack.
"They're having pain and they're trying to seek out solutions at that time, so we really try and leverage that as much as possible, because that was something we identified at our launch that.because of the lack of innovation in the category, there was a lack of credible resources on the Internet for patients to turn to. So you search on 'gout' and you're getting a lot of home remedies and those types of things"
Takeda's Gout.com is the destination for its unbranded efforts, while its Gout Smart program offers interactive discussion guides and other features aimed at getting patients into treatment.
Fine-tuning the consumer channel
Part of what's opening up the consumer channel to brands with smaller audiences is the availability of tools that facilitate much more precise targeting.
"There's been an evolution in the tools available and how we approach media," says Novo Nordisk's Jeremy Shepler, associate director, marketing" While zero waste is never going to be something any marketer can achieve, it's certainly something we can strive for, and what's being offered todav allows us to become much more targeted. I don't want to say syndicated research is out the door, but things have evolved."
Newer entrants likeTRA and Crossix are shaking up the measurement and analytics game, offering advertisers a means of getting closer to their targets. For example, through a partnership with IMS Health, TRA can match its TV set top box data to prescriber-level data telling them what drugs an (anonymized) household is taking.
"That tool is now given to our media agency, which allows them to pick the best mix, whatever it may be, to make sure we're in front of the people most meaningful to us" says Shepler. "And on the back end. we can now look at people exposed to our advertising and do ROI-based network-level buys. We can go back and see at what point we lose people and where we have the greatest conversion rate.This is fundamentally different from how media agencies have bought in the past."
At the same time, so-called demand service providers, or DSPs, operate as virtual auctioneers of media inventory, making instantaneous buys at the lowest price, much as today's electronic slock exchanges allow for automated trades at light speed.